LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)-Reference-Cited by-同舟云学术

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Published:2021-09 Issue: Volume:32 Page:S1290-S1291
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hortobagyi G.N.,Stemmer S.M.,Burris H.A.,Yap Y.S.,Sonke G.S.,Hart L.,Campone M.,Petrakova K.,Winer E.P.,Janni W.,Conte P.F.,Cameron D.,André F.,Arteaga C.,Zarate J.P.,Chakravartty A.,Taran T.,Le Gac F.,Serra P.,O'Shaughnessy J.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study;Journal of Modern Oncology;2024-03-05

2. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer;Cancer Gene Therapy;2024-02-26

3. Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review);Oncology Letters;2024-02-08

4. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer;European Journal of Cancer;2024-02

5. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort;European Journal of Cancer;2024-01